Genolution

Genolution Revenue per Share

The Revenue per Share of Genolution (225220.KQ) as of Oct 22, 2026 is 520.24 KRW. In the previous year, Revenue per Share was 395.20 KRW — a change of 31.64% (higher).

Revenue per Share

520.24KRW

YoY

31.64%

Last updated:

Revenue per Share of Genolution is 2025 520.24 KRW. Revenue per Share of Genolution was 2024 395.20 KRW. It decreases by 31.64% higher compared to the previous year.

The Genolution Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2018
492.59 KRW
Jan 1, 2019
656.93 KRW
Jan 1, 2020
8,916.19 KRW
Jan 1, 2021
3,983.85 KRW
Jan 1, 2022
2,109.77 KRW
Jan 1, 2023
540.61 KRW
Jan 1, 2024
395.20 KRW
Jan 1, 2025
520.24 KRW
The Genolution Revenue per Share history
YEARRevenue per ShareYoY
520.24KRW+31.64%
395.20KRW-26.90%
540.61KRW-74.38%
2,109.77KRW-47.04%
3,983.85KRW-55.32%
8,916.19KRW+1,257.26%
656.93KRW+33.36%
492.59KRW+18.18%
416.81KRW+57.79%
264.15KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Revenue per Share of Genolution is 520.24 KRW in 2025.

Revenue per Share of Genolution changed from 395.20 KRW to 520.24 KRW, representing a 31.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Genolution since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genolution

All Key Metrics — Genolution